CSI attended and exhibited at Outsourcing in Clinical Trials 2022 in Barcelona on 4th-5th May. It was an insightful conference as always, and we learned a lot from fellow speakers and attendees.
The main themes of this year’s OCT 2022 conference were:
Clearly the pandemic has accelerated the need for flexible and innovative clinical trial solutions. Now, the provision of care and administration of medicines at the patients’ home is accepted as the new norm.
At CSI, we have long been advocates of direct to patient supply. Direct to patient supply is an effective way to minimise disruption to the patients’ life and improve their clinical trial experience.
Technology provides many options that can facilitate the conduct of clinical trials, including:
CSI uses advance technologies to give us complete visibility of the medicines we supply to clinical trials. Technology enables us to provide flexible supply solutions based on patient recruitment and demand, as well as firm control to minimise waste at site level.
Oncology studies represent a significant portion of clinical trials conducted worldwide. They do, however, present several challenges including patient recruitment. It is therefore critical to improve the efficiency of conducting clinical trials to overcome these challenges. At OCT Europe 2022, Joshua Ondatje from Worldwide Clinical Trials gave an excellent presentation exploring adaptive designs that are more efficient, informative, and ethical.
CSI has outstanding experience and expertise in supplying oncology medicines for trials all over the world, from Brazil and Mexico to Europe and China.
CSI: the science based clinical trial supply leader
Back to resources